Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17

International Journal of Cancer

Volumn 133, Issue 7, 2013, Pages 1557-1566

  Chitadze, Guranda ^a   Lettau, Marcus ^a   Bhat, Jaydeep ^a   Wesch, Daniela ^a   Steinle, Alexander ^b   Fürst, Daniel ^c   Mytilineos, Joannis ^c   Kalthoff, Holger ^a   Janssen, Ottmar ^a   Oberg, Hans Heinrich ^a   Kabelitz, Dieter ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

ADAM10; ADAM17; MICA; MICB; NKG2D ligands; shedding

Indexed keywords

ADAM 17 PROTEIN; ADAM10 ENDOPEPTIDASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN MOLECULE A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN MOLECULE B; METALLOPROTEINASE; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN SHEDDING; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL SPECIFICITY; CELL SURFACE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MALIGNANT NEOPLASTIC DISEASE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN SECRETION; RNA INTERFERENCE; SUPERNATANT; TUMOR ESCAPE; TUMOR IMMUNITY;

ADAM10; ADAM17; MICA; MICB; NKG2D LIGANDS; SHEDDING;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTIGENS, CD9; BREAST NEOPLASMS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CYTOKINES; DIPEPTIDES; EXOSOMES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; MALE; MATRIX METALLOPROTEINASE INHIBITORS; MEMBRANE PROTEINS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE;

EID: 84880273084     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28174     Document Type: Article

References (50)

1. Raulet DH,. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-90.
2. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
3. Rincon-Orozco B, Kunzmann V, Wrobel P, et al. Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol 2005; 175: 2144-51.
4. Andre P, Castriconi R, Espeli M, et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol 2004; 34: 961-71.
5. Groh V, Rhinehart R, Randolph-Habecker J, et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-60.
6. Das H, Groh V, Kuijl C, et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83-93.
7. Groh V, Bahram S, Bauer S, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445-50.
8. Mincheva-Nilsson L, Nagaeva O, Chen T, et al. Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J Immunol 2006; 176: 3585-92.
9. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, et al. NKG2D ligands: key targets of the immune response. Trends Immunol 2008; 29: 397-403.
10. Mistry AR, O'Callaghan CA,. Regulation of ligands for the activating receptor NKG2D. Immunology 2007; 121: 439-47.
11. Zafirova B, Wensveen FM, Gulin M, et al. Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 2011; 68: 3519-29.
12. Hayakawa Y,. Targeting NKG2D in tumor surveillance. Expert Opin Ther Targets 2012; 16: 587-99.
13. Coudert JD, Scarpellino L, Gros F, et al. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 2008; 111: 3571-8.
14. Coudert JD, Zimmer J, Tomasello E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005; 106: 1711-17.
15. Nausch N, Cerwenka A,. NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944-58.
16. Robinson J, Mistry K, McWilliam H, et al. The IMGT/HLA database. Nucleic Acids Res 2011; 39: D1171-D1176.
17. Bahram S, Inoko H, Shiina T, et al. MIC and other NKG2D ligands: from none to too many. Curr Opin Immunol 2005; 17: 505-9.
18. Salih HR, Rammensee HG, Steinle A,. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-102.
19. Salih HR, Holdenrieder S, Steinle A,. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 2008; 13: 3448-56.
20. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-8.
21. Groh V, Smythe K, Dai Z, et al. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006; 7: 755-62.
22. Rebmann V, Schutt P, Brandhorst D, et al. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol 2007; 123: 114-20.
23. Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006; 55: 1584-9.
24. Marten A, von Lilienfeld-Toal M, Buchler MW, et al. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 2006; 119: 2359-65.
25. Wu JD, Higgins LM, Steinle A, et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004; 114: 560-8.
26. Wu JD, Atteridge CL, Wang X, et al. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 2009; 15: 632-40.
27. Waldhauer I, Steinle A,. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66: 2520-6.
28. Salih HR, Goehlsdorf D, Steinle A,. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 2006; 67: 188-95.
29. Sun D, Wang X, Zhang H, et al. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int 2011; 35: 569-74.
30. Liu G, Atteridge CL, Wang X, et al. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 2010; 184: 3346-50.
31. Kohga K, Takehara T, Tatsumi T, et al. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010; 51: 1264-73.
32. Waldhauer I, Goehlsdorf D, Gieseke F, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68: 6368-76.
33. Boutet P, guera-Gonzalez S, Atkinson S, et al. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 2009; 182: 49-53.
34. Sipos B, Moser S, Kalthoff H, et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003; 442: 444-52.
35. Ludwig A, Hundhausen C, Lambert MH, et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005; 8: 161-71.
36. Ashiru O, Boutet P, Fernandez-Messina L, et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010; 70: 481-9.
37. Fürst D, Solgi G, Recker K, et al. Sequence-based typing of major histocompatibility complex class I chain-related gene A alleles by use of exons 2-5 information. Tissue Antigens 2011; 77: 201-5.
38. Huovila AP, Turner AJ, Pelto-Huikko M, et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005; 30: 413-22.
39. Frigoul A, Lefranc M-P,. MICA: standardized IMGT allele nomenclature, polymorphisms and diseases. Recent Res Devel Human Genet 2005; 3: 95-145.
40. Reiss K, Ludwig A, Saftig P,. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther 2006; 111: 985-1006.
41. Aguera-Gonzalez S, Boutet P, Reyburn HT, et al. Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol 2009; 182: 4800-8.
42. Blobel CP,. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6: 32-43.
43. Mochizuki S, Okada Y,. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98: 621-8.
44. Seals DF, Courtneidge SA,. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17: 7-30.
45. Gooz M,. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010; 45: 146-69.
46. Aguera-Gonzalez S, Gross CC, Fernandez-Messina L, et al. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur J Immunol 2011; 41: 3667-76.
47. Dall'olio F, Malagolini N, Trinchera M, et al. Mechanisms of cancer-associated glycosylation changes. Front Biosci 2012; 17: 670-99.
48. Mashima T, Seimiya H, Tsuruo T,. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009; 100: 1369-72.
49. Planey SL, Zacharias DA,. Palmitoyl acyltransferases, their substrates, and novel assays to connect them (Review). Mol Membr Biol 2009; 26: 14-31.
50. Kaiser BK, Yim D, Chow IT, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007; 447: 482-6.